A Witney-based company using a powerful computer-based approach to drug discovery, has begun experimental testing on the first set of compounds for the treatment of COVID-19.
The Company will work with Wuhan, China-based R&D company WuXi AppTec to perform the studies.
E-therapeutics plc has created two unique and productive technologies. The first is Network-driven Drug Discovery (“NDD”), based on artificial intelligence. NDD allows the more efficient discovery of new and better drugs.
The second is Genome Associated Interaction Networks (“GAINs”). Based on the company’s NDD, GAINs analyses human genetic data to understand the mechanisms that cause disease. e-therapeutics says GAINs has the potential to uncover unrecognised disease processes and pathways and can enable the discovery of novel drugs, diagnostics and biomarkers in a way not previously possible.
In March, the company announced that it was looking at drugs that have already been approved to identify whether they can be repurposed for the treatment of COVID-19.
In a statement, the company said: “An initial compound set, which we believe has the potential to address both viral replication and the associated excessive immune response, will be tested by WuXi AppTec utilising its relevant cell-based assays.
Ali Mortazavi, Executive Chairman of e-therapeutics, said: “I am pleased to report progress on our contribution to the fight against COVID-19, advancing from the computational stage of our project into experimental work. We are pursuing a multipronged effort for this project and will continue to provide updates as further data becomes available.”